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Condensation 
The beneficial effect of aspirin in the prevention of preterm preeclampsia may not 
apply in pregnancies with chronic hypertension. 
 
Short version of article title 
Subgroup analysis of ASPRE trial  
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ABSTRACT 
Objective: To examine whether there are differences in the effect of aspirin on the 
incidence of preterm-PE in the ASPRE trial in subgroups defined according to 
maternal characteristics and medical and obstetrical history.  
Study design: This was a secondary analysis of data from the ASPRE trial. In 
ASPRE women with singleton pregnancies had screening by means of an 
algorithm that combines maternal factors and biomarkers at 11-13 weeks’ 
gestation. Those with an estimated risk for preterm-PE of >1 in 100 were invited to 
participate in a double-blind trial of aspirin (150 mg/day) vs. placebo from 11 to 14 
until 36 weeks’ gestation. Aspirin was associated with a significant reduction in the 
incidence of preterm-PE with delivery at <37 weeks’ gestation, which was the 
primary outcome (odds ratio 0.38; 95% confidence interval, 0.20 to 0.74; 
P=0.004). Subgroup analysis was performed to assess evidence of differences in 
the effect of aspirin on incidence of preterm-PE in subgroups defined by maternal 
age (<30 and ≥30 years), body mass index (<25 and ≥25 kg/m2), racial origin 
(Afro-Caribbean, Caucasian and other), method of conception (natural and 
assisted), cigarette smoking (smoker and non-smoker), family history of PE 
(present and absent), obstetrical history (nulliparous, multiparous with previous 
PE and multiparous without previous PE), history of chronic hypertension (present 
and absent). Interaction tests were performed on the full data set of patients in the 
intention to treat population and on the data set of patients who took > 90% of the 
prescribed medication. Results are presented as forest plot with P values for the 
interaction effects, group sizes, event counts and estimated odds ratios. We 
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examined whether the test of interaction was significant at the 5% level with a 
Bonferroni adjustment for multiple comparisons. 
Results: There was no evidence of heterogeneity in the aspirin effect in subgroups 
defined according to maternal characteristics and obstetrical history. In 
participants with chronic hypertension preterm-PE occurred in 10.2% (5/49) in the 
aspirin group and in 8.2% (5/61) in the placebo group (adjusted odds ratio 1.29, 
95% confidence interval, 0.33 to 5.12); the respective values in those without 
chronic hypertension were 1.1% (8/749) in the aspirin group and 3.9% (30/761) in 
the placebo group (adjusted odds ratio 0.27, 95% confidence interval, 0.12 to 
0.60). In all participants with adherence of >90% the adjusted odds ratio in the 
aspirin group was 0.24 (95% CI 0.09 to 0.65), in the subgroup with chronic 
hypertension it was 2.06 (95% CI 0.40 to 10.71) and in those without chronic 
hypertension it was 0.05 (95% CI 0.01 to 0.41). For the complete data set the test 
of interaction was not significant at the 5% level (p=0.055), but in those with 
adherence >90%, after adjustment for multiple comparisons, the interaction was 
significant at the 5% level (p=0.0019).  
Conclusions: The beneficial effect of aspirin in the prevention of preterm 
preeclampsia may not apply in pregnancies with chronic hypertension. There was 
no evidence of heterogeneity in the aspirin effect in subgroups defined according 
to maternal characteristics and obstetrical history. 
 
Key words: First trimester screening, Aspirin, ASPRE trial, Preeclampsia, 
Chronic hypertension, Uterine artery Doppler, Mean arterial blood pressure, 
Placental growth factor, Pregnancy associated plasma protein-A. 
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Introduction 
This is a secondary analysis of data from the ASPRE (Combined Multimarker 
Screening and Randomized Patient Treatment with Aspirin for Evidence-Based 
Preeclampsia Prevention) trial.1 In the trial, women with singleton pregnancies 
identified as being at high-risk of preterm preeclampsia (PE), by means of an 
algorithm that combines maternal factors and biomarkers at 11-13 weeks’ 
gestation,2 were randomized to receive aspirin (150 mg/day) vs. placebo from 11 
to 14 until 36 weeks’ gestation. Preterm-PE with delivery at <37 weeks’ gestation, 
which was the primary outcome, occurred in 1.6% (13/798) participants in the 
aspirin group, as compared with 4.3% (35/822) in the placebo group (odds ratio in 
the aspirin group with adjustment for the effect of the estimated risk for 
preterm-PE at screening and participating center 0.38; 95% confidence interval, 
0.20 to 0.74; P = 0.004). 
The objective of this study is to examine whether there are differences in the 
effect of aspirin on the incidence of preterm-PE in subgroups defined according to 
maternal characteristics and medical and obstetrical history. 
 
Methods 
The ASPRE trial was conducted at 13 maternity hospitals in the United Kingdom, 
Spain, Italy, Belgium, Greece, and Israel.1 In the 13 participating hospitals routine 
screening for preterm-PE was carried out at 11-13 weeks’ gestation by an 
algorithm combining maternal demographic characteristics and medical and 
obstetrical history,3 and the measurements of mean arterial pressure,4 uterine 
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artery pulsatility index5 and serum pregnancy associated plasma protein-A and 
placental growth factor (PAPP-A and PlGF 1-2-3TM kits, DELFIA® Xpress random 
access platform; PerkinElmer Inc. Wallac Oy, P.O.Box 10, 20101 Turku, Finland). 
The eligibility criteria for the trial were maternal age >18 years, no serious mental 
illness or learning difficulties, singleton pregnancy with live fetus with no major 
abnormality demonstrated on the 11-13 weeks scan and estimated risk for 
preterm-PE of >1 in 100.1 Participants completed a questionnaire on their 
demographic characteristics and medical and obstetrical history and the 
questionnaire was then reviewed by a doctor together with the woman. 
Consequently, the diagnosis of chronic hypertension was based on what was 
reported by the participants at the visit at 11-13 weeks’ gestation. 
The primary outcome measure was delivery with PE at <37 weeks’ gestation. 
Preeclampsia was defined according to the International Society for the Study of 
Hypertension in Pregnancy.6 The systolic blood pressure should be >140 mmHg 
and/or the diastolic blood pressure should be >90 mmHg on at least two 
occasions four hours apart developing after 20 weeks of gestation in previously 
normotensive women. Hypertension should be accompanied by proteinuria of 
>300 mg in 24 hours or two readings of at least ++ on dipstick analysis of 
midstream or catheter urine specimens if no 24-hour collection is available. In PE 
superimposed on chronic hypertension significant proteinuria (as defined above) 
should develop after 20 weeks of gestation in women with known chronic 
hypertension.  
Adherence was calculated as a percentage of the reported intake of tablets to 
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the total number that participants were expected to have taken between the date 
of randomization and the date of the visit at 36 weeks’ gestation or the date of 
delivery if delivery occurred before 36 weeks.  
Approval for the trial was obtained from the relevant research ethics committee 
and competent authority in each country in which the trial was conducted. These 
include the NHS Health Research Authority in the UK; Ethics Committee of Clinic 
University Hospital Virgen de la Arrixaca, Murcia, Spain; Ethics Committee of 
University Hospital of San Cecilio, Granada, Spain; Comite de etica e 
investigacion, Hospital Universitario Nuestra Senora de la Candelaria, Tenerife, 
Canary Islands; Ethics Committee Zone B, Milan, Italy; Ethics Committee of 
University of Brugmann, Brussels, Belgium; Ethics Committee of Greece; Ministry 
of Health and Rabin Medical Center Ethics Committee, Israel. 
 
Statistical analyses 
Interactions were tested to assess the evidence whether the aspirin effect on the 
incidence of preterm-PE differed between subgroups defined by maternal age 
(<30 and ≥30 years), body mass index (<25 and ≥25 kg/m2), racial origin 
(Afro-Caribbean, Caucasian and other), method of conception (natural and 
assisted by ovulation induction drugs or in vitro fertilization), cigarette smoking 
(smoker and non-smoker), family history of PE (present and absent), obstetrical 
history (nulliparous, multiparous with previous pregnancy complicated by PE and 
multiparous without PE), history of chronic hypertension (present and absent). For 
the medical conditions systemic lupus erythematosus, antiphospholipid syndrome 
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and diabetes mellitus, there were too few preterm-PE events for logistic 
regression. The subgroup analyses for obstetrical history were pre-specified but 
those for maternal characteristics and medical history were post hoc. 
Interaction was tested by the addition of terms to the logistic regression model 
that was used for the primary analysis.1 The estimated risk of preterm-PE at 
screening and the participating centre were included as covariates. In these 
analyses, continuous variables were grouped as indicated above. The analysis of 
these was repeated respecting the continuous scale and there was no substantive 
difference in the results. Treatment effects (odds ratios aspirin/placebo) were 
estimated by parameterizing the logistic regression model so that it included 
coefficients corresponding to within group log odds ratios. This is more efficient 
than separate analyses of different subgroups. Interaction tests were performed 
on the full data set of patients in the intention to treat population and on the data 
set comprising those patients who took > 90% of the prescribed medication. 
Results are presented as a forest plot with P values for the interaction effects, 
group sizes, event counts and estimated odds ratios (aspirin/ placebo). We 
examined whether the test of interaction was significant at the 5% level; since the 
number of planned tests was 8 the P values should be compared to 0.05/8 = 
0.00625 to determine significance at the 5% level with a Bonferroni adjustment for 
multiple comparisons. 
Having identified those with chronic hypertension as a credible subgroup who 
may not benefit from taking aspirin, estimates of the effects of treatment according 
to history of chronic hypertension (present and absent) and adherence ≥90%were 
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obtained from the logistic regression model used for the primary analysis.1 The 
statistical software package R was used for data analyses.7  
 
Results  
In the ASPRE trial preterm-PE occurred in 13 of 798 participants (1.6%) in the 
aspirin group, as compared with 35 of 822 (4.3%) in the placebo group (adjusted 
odds ratio in the aspirin group, 0.38; 95% confidence interval, 0.20 to 0.74; P = 
0.004).1  
There was no evidence of heterogeneity in the aspirin effect in subgroups 
defined according to racial origin, maternal age, body mass index, method of 
conception, smoking, family history of PE, obstetrical history, and history of 
pre-existing medical conditions, except for chronic hypertension in which there 
may not be a beneficial effect from aspirin (Figure 1). The subgroup of medical 
conditions other than chronic hypertension is not shown in the figure because 
there were no cases of preterm-PE in the 19 participants of the aspirin group and 
only 1 in the 8 of the placebo group (odds ratio 0.00, 95 CI 0.00 to infinity). 
In participants with chronic hypertension, preterm-PE occurred in 10.2% 
(5/49) in the aspirin group and in 8.2% (5/61) in the placebo group (odds ratio 
1.29, 95% confidence interval, 0.33 to 5.12); the respective values in those 
without chronic hypertension were 1.1% (8/749) in the aspirin group and 3.9% 
(30/761) in the placebo group (odds ratio 0.27, 95% confidence interval, 0.12 to 
0.60) (Figure 2). In all participants with adherence of >90% the adjusted odds ratio 
in the aspirin group was 0.24 (95% CI 0.09 to 0.65), in the subgroup with chronic 
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hypertension it was 2.06 (95% CI 0.40 to 10.71) and in those without chronic 
hypertension it was 0.05 (95% CI 0.01 to 0.41). For the complete data set the test 
of interaction was not significant (p=0.055 without and 0.44 with Bonferroni 
correction), but in those with adherence >90% the interaction was significant 
(p=0.0019 without and 0.015 with Bonferroni correction).  
 
Comment 
Principal findings of this study 
The ASPRE trial demonstrated that, in women with singleton pregnancies 
identified by means of first trimester screening as being at high risk for 
preterm-PE, the administration of aspirin at a dose of 150 mg/day from 11 to 14 
weeks until 36 weeks’ gestation reduces the incidence of preterm-PE by 
approximately 60%.1 A secondary analysis demonstrated that the beneficial effect 
of aspirin depends on adherence and the reduction in incidence of preterm-PE 
may be about 75% in those with adherence of >90% and only 40% in those with 
adherence of <90%.8  
This subgroup analysis demonstrated that there was no evidence of 
heterogeneity in the beneficial effect of aspirin in reducing the incidence of 
preterm-PE in subgroups defined according to maternal age, body mass index, 
racial origin, method of conception, smoking, family history of PE, obstetrical 
history, and history of pre-existing medical conditions, except for chronic 
hypertension. In chronic hypertension prophylactic use of aspirin may not be 
useful in the prevention of preterm-PE. Consequently, if participants with chronic 
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hypertension were excluded from the trial, aspirin could have potentially reduced 
the incidence of preterm-PE by >70% and this reduction could have been about 
95% in those with adherence of >90%. However, there is a high degree of 
uncertainty about these post hoc findings and further evidence is needed. We are 
planning a clinical evaluation study that will address this.   
Limitations of the study  
The ASPRE trial had demonstrated the therapeutic efficacy of aspirin globally and 
the size of the treatment effect was consistent across estimated risk groups for 
preterm-PE at the time of screening.1 The estimated risk for preterm-PE was 
derived from an algorithm combining maternal factors with biomarkers2 and there 
was considerable heterogeneity in maternal characteristics and medical and 
obstetrical history in the trial population. It is for this reason that we wanted to 
ascertain whether there are differences in the therapeutic efficacy in subgroups of 
the population defined according to maternal characteristics and medical and 
obstetrical history.  
The ASPRE trial was powered for a global test of the aspirin effect in a high 
risk population. The statistical power for detecting effects in smaller subgroups of 
data is inevitably poor and only the larger interaction effects are likely to be 
detected. This problem is exacerbated by the need to account for multiple 
comparisons. It is reassuring that the estimated odds ratios for groups other than 
chronic hypertension show a degree of consistency. However, the confidence 
intervals are very wide and we cannot rule out clinically important interaction 
effects.  
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Clinical implications of the study 
The argument in favour of first-trimester screening for PE has been strengthened 
by the findings of the ASPRE trial which demonstrated that in women identified by 
such screening as being at high-risk for preterm-PE administration of aspirin can 
reduce substantially the incidence of the disease.1,9 The results may help resolve 
the controversy concerning the relation of the therapeutic effect of aspirin with the 
gestational age at onset of therapy and the necessary dose of the drug.10-13  
The subgroup analysis demonstrated that in women with chronic hypertension 
aspirin may not be useful in the prevention of preterm-PE. The European 
Medicines Agency proposed that the credibility of a finding of inconsistency for the 
therapeutic effect in a subgroup, compared to the whole trial population, requires 
that tests of interaction are statistically significant, there is supportive evidence 
from other trials, and there is a biological plausibility for the findings.14 We found 
that in the subgroup with chronic hypertension and adherence >90% the test of 
interaction was highly significant. Our results that aspirin may not be effective in 
women with chronic hypertension are concordant with those of a meta-analysis of 
individual patient data from 32 217 women recruited to 31 trials on the use of 
antiplatelet agents, mainly aspirin, for prevention of PE which reported a subgroup 
analysis according to pre-existing hypertension.15 The relative risk (with 95% 
confidence interval) for all women was 0.90 (0.84 to 0.97), in the subgroup of 
women with pre-existing hypertension it was 0.97 (0.84 to 1.12) and in those 
without pre-existing hypertension it was 0.88 (0.81 to 0.96); however, the test of 
interaction was non-significant (p=0.28).  
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In terms of biological plausibility there is some evidence of differences 
between chronic hypertension and other factors in the pathogenesis of PE. 
Chronic hypertension, found in 1-2% of pregnancies, is the strongest risk factor 
for PE compared to other factors in maternal demographic characteristics and 
medical history.3 In women with chronic hypertension the risk of both preterm and 
term PE is 5-6 times higher than in women without this medical disorder.16 
Preterm-PE is associated with impaired trophoblastic invasion of the maternal 
spiral arteries, reduced placental perfusion, oxidative stress that triggers off 
release of trophoblast-derived factors which cause generalized endothelial 
dysfunction and an exaggerated inflammatory response that underlines many of 
the changes observed in PE.17-21 In chronic hypertension there is endothelial 
dysfunction and inflammation even before pregnancy and it is possible that in this 
condition PE can develop in the absence or less severe degree of impaired 
placentation because the pre-existing endothelial dysfunction is exacerbated by 
the physiological burden of pregnancy.22-27 
Conclusions  
In pregnancies at high risk of preterm-PE identified by screening at 11-13 weeks’ 
gestation administration of aspirin reduces the incidence of preterm-PE by about 
60%.1 Post-hoc analysis suggests that the reduction in preterm-PE may be 75% if 
adherence to medication is >90%8 and could be as high as 95% if women with 
chronic hypertension are excluded. These analyses also suggest that in women 
with chronic hypertension aspirin may not reduce the incidence of preterm-PE.  
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Figure legends 
 
Figure 1. Odds ratio for preterm preeclampsia in the aspirin group with 95% 
confidence intervals in different subgroups defined according to maternal 
characteristics and medical and obstetrical history. The P values and confidence 
intervals are not adjusted for multiple comparisons. We performed 8 tests and the 
P values should be compared to 0.05/8 = 0.00625 to determine significance at the 
5% level with a Bonferroni adjustment for multiple comparisons.   
 
Figure 2. Odds ratio for preterm preeclampsia in the aspirin group with 95% 
confidence intervals in the total population and in those with and without chronic 
hypertension and in subgroups with adherence of >90%.  
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